2014


To access this material please log in or register

Register Authorize
2014/№4

New oral anticoagulants and warfarin: advantages, disadvantages and clinical practice

Kozlova T. V., Taratuta T. V., Rumyantsev A. A.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: anticoagulants, warfarin, treatment

DOI: 10.18087/rhj.2014.4.1960

The article provides brief description of new oral anticoagulants, discusses advantages and disadvantages of new drugs, and analyzes major clinical studies focused on comparison of efficacy and safety of new oral anticoagulants and warfarin used in venous thrombosis and atrial fibrillation. Tactics of selecting «first-line» drugs for treatment and prevention of venous and arterial thromboses are discussed.
  1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131 (7):492–501.
  2. Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999 Mar 25;340 (12):901–7.
  3. Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do random-ized trials translate into clinical practice? JAMA. 2003 Nov 26;290 (20):2685–92.
  4. Dowlatshahi D, Butcher KS, Asdaghi N et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012 Jul;43 (7):1812–7.
  5. McCrory DC, Matchar DB, Samsa G et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995 Feb 13;155 (3):277–81.
  6. McCormick D, Gurwitz JH, Goldberg RJ et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001 Nov 12;161 (20):2458–63.
  7. van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103 (6):1116–1127.
  8. Harenberg J, Marx S, Weiss C et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012 Jul;10 (7):1433–6.
  9. Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37 (1):74–81.
  10. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009;361 (24):2342–2352.
  11. Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368 (8):709–18.
  12. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363 (26):2499–2510.
  13. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366 (14):1287–97.
  14. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369 (9):799–808.
  15. Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368 (8):699–708.
  16. Büller HR, Décousus H, Grosso MA et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369 (15):1406–15.
  17. Vandvik PO, Lincoff AM, Gore JM et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 (2 Suppl): e637S-668S.
  18. van der Hulle T, Kooiman J, den Exter PL et al. Effectiveness and safety of novel oral anticoagulants compared with vitamin K-antagonists in the treatment of acute symptomatic venous thromboembolism - a systematic review and meta-analysis. J Thromb Haemost. 2013;13 (12): 2083–2090.
  19. Sardar P, Chatterjee S, Mukherjee D et al. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials. Drugs. 2013;73 (11):1171–82.
  20. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial?brillation. N Engl J Med. 2009;361 (12):1139–1151.
  21. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomi­zed controlled trials. Arch Intern Med. 2012;172 (5):397–402.
  22. Patel MR, Mahaffey KW, Garg J et al. for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365 (10):883–891.
  23. Granger CB, Alexander JH, McMurray JJ et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365 (11):981–992.
  24. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369 (22):2093–104.
  25. Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383 (9921):955–62.
  26. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013 May;15 (5):625–51.
  27. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14 (10):1385–413.
  28. Ageno W, Crowther M, Baglin T et al. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013 Jan;11 (1):177–9.
  29. Рекомендации РКО, ВНОА и АССХ «Диагностика и лечение фибрилляции предсердий», 2012. Доступно на: http://scardio.ru / content / Guidelines / FP_rkj_13.pdf
  30. White HD, Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167 (3):239–245.
  31. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37 (4):1070–1074.
  32. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013 Nov;144 (5):1555–63.
  33. Sørensen R, Gislason G, Torp-Pedersen C et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013; 3 (5): e002758.
Kozlova T. V., Taratuta T. V., Rumyantsev A. A. New oral anticoagulants and warfarin: advantages, disadvantages and clinical practice. Russian Heart Journal. 2014;78 (4):234–244

To access this material please log in or register

Register Authorize
Ru En